English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51881511    線上人數 :  802
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"liu c h"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 391-415 / 1570 (共63頁)
<< < 11 12 13 14 15 16 17 18 19 20 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-09-04T06:11:51Z Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; JIA-HORNG KAO; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:50Z Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients Hsu C.-S.; Hsu S.-J.; Chen H.-C.; Liu C.-H.; Jeng J.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:50Z Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection Su T.-H.; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen C.-L.; Chen P.-J.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:49Z Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype Huang C.-F.; Yu M.-L.; JIA-HORNG KAO; Tseng T.-C.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.H.H.; Chuang W.-L.; Liu C.-H.
臺大學術典藏 2021-09-04T06:11:48Z Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C Su T.-H.; Liu C.-H.; Liu C.-J.; Chen C.-L.; Ting T.-T.; Tseng T.-C.; Chen P.-J.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:45Z IL28B genotype on HCV infection in Asia Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:45Z Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Yang W.-T.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:44Z Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:43Z Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy Su T.-H.; Liu C.-J.; Yang H.-C.; Jeng Y.-M.; Cheng H.-R.; Liu C.-H.; Tseng T.-C.; Ling T.-Y.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:42Z Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin Chen M.-Y.; Liu C.-H.; Chen T.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:41Z Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters Tseng T.-C.; Liu C.-J.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:40Z Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications Wu H.-L.; JIA-HORNG KAO; Chen T.-C.; Wu W.-H.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen D.-S.; Chen P.-J.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:40Z Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Chen T.-C.; Tseng T.-C.; Liu C.-H.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:37Z Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: Optimizing use of peginterferon alfa Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:37Z Triple therapy for hepatitis C virus infection in patients receiving hemodialysis Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:34Z Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: Comparison of genotypes B and C at various immune stages Liu C.-J.; Chen T.-C.; Chen P.-J.; Wang H.-Y.; Tseng T.-C.; Cheng H.-R.; Liu C.-H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:32Z Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B Lin C.-L.; Liu C.-H.; Wang C.-C.; Liang C.-C.; Su T.-H.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:31Z Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients Wang C.-C.; Liu C.-H.; Lin C.-L.; Wang P.-C.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:30Z Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:27Z Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping Liu C.-H.; Liang C.-C.; Liu C.-J.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy Liang C.-C.; Liu C.-H.; Chung C.-S.; Lin C.-K.; Su T.-H.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:25Z Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏 2021-09-04T06:11:25Z Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:23Z Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO

顯示項目 391-415 / 1570 (共63頁)
<< < 11 12 13 14 15 16 17 18 19 20 > >>
每頁顯示[10|25|50]項目